Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study patients | Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition | within the first 6-24 hours after antiplatelet drug loading dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with acute coronary syndrome who received a loading dose of prasugrel within 6 and 24h.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Geneva | Geneva | Canton of Geneva | 1205 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Plasma